I contacted Salspera and got this response from the CEO…
————————-
“Unfortunately, we do not have sufficient data to date with GEM/Abraxane. The data we have with FOLFIRINOX is much further along and highly encouraging.

We can discuss our therapy with your oncologist at the Mayo if this is of interest. Here is a summary that was published recently on our study:

Patient diagnosis: Stage 4, metastasized pancreatic cancer
Treatment: Modified FOLFIRINOX in conjunction with Saltikva, every 2 weeks
Modifications of FOLFIRINOX: Dose reductions, component exemptions, chemo holidays
Number of patients in this arm: 18
Mode of administration for Saltikva: Oral

Overall median survival: 19 months for our group versus 12 months for standard of care at the site
Progression free survival: 15 months in our group versus 5.8 months for standard of care at the site
Safety, Adverse events or serious adverse events: Over 140 events recorded, none of which were found to be attributable to Saltikva; all adverse events were attributed to the chemotherapy by the site oncologists.

Significant and sustained reduction of CA 19.9 and CEA levels
Significant changes in immune modulation with T-cells and NK cells
Significant reduction in tumor sizes shown in CT and PET, analyzed by RECIST 1.1 criteria
Effect was consistent despite significant modifications of the chemotherapy or multiple chemo-holidays”

Further notes:
FDA Orphan Drug Designation
FDA Fast Track designation

Best regards,

--
Eddie Moradian , PhD
Chief Executive Officer

Salspera, Inc.
Cell: (651) 402 5587